These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 29767586)

  • 1. The swinging pendulum of cancer immunotherapy personalization.
    Abraham TS; Snook AE
    Per Med; 2017 May; 14(3):259-270. PubMed ID: 29767586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
    Sivaganesh V; Promi N; Maher S; Peethambaran B
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
    Klener P; Etrych T; Klener P
    Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
    Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
    Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-engaging therapies - BiTEs and beyond.
    Goebeler ME; Bargou RC
    Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunotherapies for hematologic malignancies.
    Nelson MH; Paulos CM
    Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immune therapy for lymphoid malignancies: recent advances.
    Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
    Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.